ClinicalTrials.gg
CompletedNCT06048588Updated Sep 22, 2026

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

A Phase 1/2 interventional study of YN001 and Placebo for YN001 in Atherosclerotic Cardiovascular Disease, sponsored by Beijing Inno Medicine Co., Ltd.. Completed at 6 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Beijing Inno Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies in Atherosclerosis with a site in China — 36 open to participants now, 48 under way, 11 of them phase 3. Atherosclerosis · China.

Enrollment
46th of 79
144 · median 200
Started
2023
with 4 others
Phase 1/2
5 of 113
2 open now
Registered
77th of 113
by date
Lead sponsor
3 of 113
Beijing Inno Medicine Co., Ltd.

Among the 113 studies in Atherosclerosis with a site in China, this one is the 46th largest by enrollment of the 79 interventional ones that give a count, is one of 5 that started in 2023, is one of 5 in phase 1/2, and was the 77th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

36 of the 113 studies in Atherosclerosis with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Atherosclerosis with a site in China, or all of them as a file.
02

Study summary

This study consists of two parts. The SAD and MAD of part I are a randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult subjects. The MAD expansion cohort of part I is single arm and multipal ascending dose in heallthy subjects. Part II (phase Ib/IIa) is a multicenter, randomized, controlled, open label, multiple ascending dose study in patients with coronary atherosclerosis.

Read the detailed description

Part I (phase Ia) is consists of 2 sections. The sections 1 is designed to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of intravenously administered YN001, and to evaluate the effect of SAD of intravenously administered YN001 on the QT/QTc interval, and the immunogenicity of MAD of intravenously administered YN001 in healthy subjects. Besides, the section 2 is designed to evaluate the safety and tolerability of multiple intravenous administration of YN001 without pre-medication or with different pre-medication regimens in Chinese healthy subjects.

Part II (phase Ib/IIa) is designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy, immunogenicity, and the effect on cytokine changes of MAD of intravenously administered YN001 in patients with coronary atherosclerosis.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part I (Phase Ia)-Inclusion criteria:

  1. Fully understand the purposes, features, and methods of the study and the possible adverse reactions, voluntarily participate in the study as a subject, and sign the ICF before performing any assessment.
  2. Chinese healthy male or female subjects between 18 and 55 years.
  3. A (BMI) of 18-28 kg/m2 (inclusive), with a body weight of at least 50 kg for males and 45 kg for females.
  4. Be in good general health at discretion of the investigator based on the results (be normal or abnormal without clinical significance) of medical history, physical examination, vital signs,12-lead , laboratory tests (Hematology; Blood chemistry; Urinalysis, Coagulation and CRP) and viral serology.
  5. Female subjects must be non-pregnant and non-lactating, and women of (including the male subject's female companion) must agree to use effective method of from the screening period to 3 months after receiving their last dose of the drug.
  6. Willing and able to comply with the requirements of protocol.

Part I (Phase Ia)-Exclusion criteria:

  1. Prior treatment with other investigational drug(s) within 3 months or 5 half-lives, whichever is longer, prior to the first dosing.
  2. Prior treatment with any prescription drugs, herbal supplements, over the counter (OTC) medication, dietary supplements (vitamins included), or any type of vaccination within 2 weeks prior to the first dosing.
  3. Presenting with history of severe food allergy (e.g., anaphylactic reaction). Mild (e.g., non-anaphylactic, ) food allergies such as lactose intolerance/ glucose intolerance are permitted.
  4. Allergy to multiple kinds of drugs or presenting with history of allergic reactions to any components of the study drug.
  5. Known any clinically abnormal diseases or factors, including but not limited to neurological, cardiovascular, hematological, hepatic, renal, gastrointestinal, respiratory, metabolic, endocrine, immunological, skeletal system diseases, or other reasons that, in the opinion of the investigator, makes the subject inappropriate for inclusion in this study.
  6. Presenting with history of myopathy/ myalgia, or susceptible to myopathy/ rhabdomyolysis.
  7. Presence of hypothyroidism.
  8. Presenting and/or relapse history (within the last 3 years) of acute or chronic bronchospastic disease (including asthma and , treated, or not treated) or cardiac dysfunction or myocardial infarction.
  9. Known inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding within 6 months prior to the first dosing.
  10. Presenting with history of pancreatic injury or pancreatitis within 6 months prior to the first dosing.
  11. Presence of symptoms of urinary obstruction or difficulty in voiding.
  12. Presenting and/ or relapse history (within the last 3 years) of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.).
  13. Evidence of major diseases that not recovered within 2 weeks prior to the first dosing, or major surgery is expected during the study.
  14. Presenting with history of impaired renal function defined by clinically significantly abnormal creatinine or BUN and/ or urea values, or abnormal urinary constituents (e.g., albuminuria).
  15. Presence of liver disease or liver injury, defined by abnormal liver function tests.
  16. Fasting triglyceride > 3.4 mmol/L.
  17. Presenting with history of ECG abnormalities, or any of the following abnormalities at screening or baseline. >470 msec for male, QTcF>480 msec for female.
  18. levels are below 120 g/L for males and 110 g/L for females at screening.
  19. Donation or blood loss is more than 400 mL within 3 months prior to screening.
  20. Use more than 10 cigarettes per day or habitual use of nicotine-containing products within 3 months prior to screening.
  21. Presenting with history of drug abuse within 12 months prior to screening, or use of any drugs within 3 months prior to screening, or a positive result of drug abuse screen at screening.
  22. Consumption of more than 14 standard drinks of alcohol per week within 3 months prior to screening, or consumption of alcohol-containing products 48 hours prior to the first dosing or having positive alcohol breath test at baseline.
  23. Positive for , , , TP-Ab.
  24. Presence of any other diseases or conditions that, in the opinion of the investigator, would make it unsuitable for the subject to participate in this study.

Part II (Phase Ib/IIa)-Inclusion criteria:

  1. Fully understand the purposes, features, and methods of the study and the possible adverse reactions, voluntarily participate in the study as a subject, and sign the ICF before performing any assessment.
  2. Chinese male or female subjects between 18 and 75 years.
  3. Patients diagnosed with confirmed coronary atherosclerosis and 25-75% stenosis determined by coronary angiography.
  4. Suspicion of vulnerable plaque based on clinical practice and determined by OCT examination.
  5. Measurable targeted segment by estimation must be at least 40 mm in length.
  6. Female subjects must be non-pregnant and non-lactating, and women of childbearing potential (including the male subject's female companion) must agree to use effective method of contraception from the screening period to 3 months after receiving their last dose of the investigational drug.
  7. Willing and able to comply with the requirements of protocol.

Part II (Phase Ib/IIa)-Exclusion criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to the first dosing.
  2. Any type of vaccination within 4 weeks prior to the first dosing.
  3. Presence of moderate or heavily calcification lesion in target segment determined by coronary angiography.
  4. Known familial hypercholesterolemia.
  5. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months, such as ventricular tachycardia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia.
  6. Presenting with history of any type of stroke (cerebral lacunar infarction excluded).
  7. Presenting with history of myopathy/ myalgia, or susceptible to myopathy/ rhabdomyolysis.
  8. Known inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding within 6 months prior to the first dosing.
  9. Presenting with history of pancreatic injury or pancreatitis within 6 months prior to the first dosing.
  10. Evidence of major diseases that not recovered within 2 weeks prior to the first dosing, or major surgery is expected during the study.
  11. Any surgical operation is planned during the study.
  12. Presenting with history of .
  13. Presence of any type of disease.
  14. Allergy to multiple food or drugs or presenting with history of allergic reactions to any components of the study drug.
  15. Prior treatment with CABG, PCI, heart transplantation, SAVR/TAVR, etc., or CABG, PCI, heart transplantation, SAVR/TAVR, etc., is planned during the study.
  16. is less than 1 year.
  17. (LVEF) \<40%.
  18. Left main coronary artery disease, defined as left main coronary artery stenosis≥50% by angiographic estimation.
  19. Uncontrolled hypertension.
  20. Active liver disease or hepatic dysfunction defined by any of , AST, or serum exceeding 1.5ULN.
  21. Presence of renal insufficiency ( \< 30 mL/min/1.73m2).
  22. Presence of hypothyroidism.
  23. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus.
  24. Positive for HBsAg, HCV, HIV, TP-Ab.
  25. Presence of any other diseases or conditions that, in the opinion of the investigator, would make it unsuitable for the subject to participate in this study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    YN001

    YN001 will be administrated intravenous by single ascending dose, multiple ascending doses weekly or twice a week.

    Drug: YN001

  • Placebo comparator
    Part I-Matching placebo for YN001

    Matching placebo for YN001 will be administrated intravenous.

    Drug: Placebo for YN001

  • Active comparator
    Part II-Rosuvastatin calcium tablets

    Rosuvastatin calcium tablets will be given by orally.

    Drug: rosuvastatin calcium tablets

Interventions

  • DrugYN001

    In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.

  • DrugPlacebo for YN001

    The injection solution to mimic the YN001

    Also known as: Placebo

  • In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days

    Also known as: Crestor®

06

What researchers measure

Primary outcomes

  1. Part I: The safety and tolerability of YN001 in healthy subjects.

    To evaluate the incidence of Adverse Events as Assessed by CTCAE v5.0, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities, Clinically Significant Physical Examination Abnormalities.

    Time frame: Up to 29 days

  2. Part I: Maximum plasma concentration(Cmax) of YN001

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects

    Time frame: Up to 168 hours of post initiation of last dose

  3. Part I: Time of maximum concentration (Tmax) of YN001

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  4. Part I: Elimination half-life (t1/2) of YN001

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  5. Part I: Area under the plasma concentration-time curve from time 0 to the collection time point of the last measurable concentration (AUC0-t) of YN001

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in healthy subjects.

    Time frame: Up to 168 hours of post initiation of last dose

  6. Part II: The safety and tolerability of intravenously administered YN001 in patients with coronary atherosclerosis.

    To evaluate the incidence of Adverse Events as Assessed by CTCAE v5.0, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities, Clinically Significant Physical Examination Abnormalities, Clinically Significant Echocardiogram Abnormalities.

    Time frame: Up to 29 days

Secondary outcomes

  1. Part I: C-QTc analysis

    To evaluate the effect of SAD of YN001 on QT/QTc interval prolongation and relationship between YN001 exposure and QT/QTc Interval changes in Chinese healthy subjects.

    Time frame: Pre-dose and up to 48 hours post initiation of infusion

  2. Part I: Immunogenicity analysis

    To evaluate the immunogenicity of MAD of intravenously administered YN001 in Chinese healthy subjects.

    Time frame: Up to 96 hours of post initiation of last dose

  3. Part I: Pharmacodynamic evaluation

    To evaluate the change LDL-C, HDL-C,TC and TG from baseline to EOT

    Time frame: Up to 96 hours of post initiation of last dose

  4. Part II: Maximum plasma concentration(Cmax) of YN001

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in patients with coronary atherosclerosis.

    Time frame: Up to 96 hours of post initiation of last dose

  5. Part II: Time of maximum concentration (Tmax) of YN001

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in patients with coronary atherosclerosis.

    Time frame: Up to 96 hours of post initiation of last dose

  6. Part II: Elimination half-life (t1/2) of YN001

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in patients with coronary atherosclerosis.

    Time frame: Up to 96 hours of post initiation of last dose

  7. Part II: Area under the plasma concentration-time curve from time 0 to the collection time point of the last measurable concentration (AUC0-t) of YN001

    To evaluate the pharmacokinetics (PK) characteristics of of intravenously administered YN001 in patients with coronary atherosclerosis.

    Time frame: Up to 96 hours of post initiation of last dose

  8. Part II: Change in percent atheroma volume (PAV) of coronary plaque comparing to baseline

    PAV will be determined by intravascular ultrasound (IVUS)

    Time frame: Up to 91 days or EOT

  9. Part II: Change in total atheroma volume (TAV) of coronary plaque comparing to baseline

    TAV will be determined by intravascular ultrasound (IVUS)

    Time frame: Up to 91 days or EOT

  10. Part II: Change in coronary minimal lumen area (MLA) comparing to baseline

    MLA will be determined by intravascular ultrasound (IVUS)

    Time frame: Up to 91 days or EOT

  11. Part II: Change in maximum lipid arc and lipid core length of coronary plaque comparing to baseline

    lipid arc and lipid core length will be determined by optical coherence tomography (OCT)

    Time frame: Up to 91 days or EOT

  12. Part II: Change in minimum fibrous cap thickness (FCT) of coronary plaque comparing to baseline

    FCT will be determined by optical coherence tomography (OCT)

    Time frame: Up to 91 days or EOT

  13. Part II: Change in detection rate of macrophage cluster within coronary plaque comparing to baseline

    detection rate of macrophage cluster will be determined by optical coherence tomography (OCT)

    Time frame: Up to 91 days or EOT

  14. Part II: Change in maximum IMT and plaque thickness

    IMT will be determined by carotid ultrasound scans

    Time frame: Up to 91 days or EOT

  15. Part II: Change in atherosclerosis plaque located at other arteries

    Other arteries plaque will be determined by CTA or MRA

    Time frame: Up to 91 days or EOT

  16. Part II: Immunogenicity analysis

    To evaluate the immunogenicity of MAD of intravenously administered YN001 in Chinese patients with coronary atherosclerosis.

    Time frame: Up to 91 days or EOT

  17. Part II: Cytokines analysis

    To evaluate the effect of MAD of intravenously administered YN001 on Cytokines levels in Chinese patients with coronary atherosclerosis.

    Time frame: Up to 91 days or EOT

  18. Part II: Pharmacodynamic analysis

    Change in LDL-C,HDL-C,TC and TG levels form baseline to EOT

    Time frame: Up to 91 days or EOT

07

Study locations

6 sites
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, Beijing Municipality 10000, China
  • Peking University first hospital
    Beijing, Beijing Municipality 100034, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei, China
  • First Hospital of Jilin University
    Changchun, Jilin 130000, China
  • Renji Hospital Shanghai Jiaotong Unv. school of Medicine
    Shanghai, Shanghai Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Apr 2025, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2023
First posted
Sep 21, 2023
StartActual
Oct 8, 2023
Primary completionActual
Apr 27, 2025
CompletionActual
Apr 27, 2025
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06048588
Lead sponsor
Beijing Inno Medicine Co., Ltd.
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Oct 8, 2023
Primary completion
Apr 27, 2025
Completion
Apr 27, 2025
Last update
Sep 22, 2026

Study contacts

Teresa Chen, Master
study director · Beijing Inno Medicine Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YN001

Start the discussion